Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure

Irvin F. Goldenberg, William R Lewis, Virgil C. Dias, J. Thomas Heywood, Wes R. Pedersen

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

The objective of this multicenter, randomized, double-blind, placebo-controlled study was to determine the safety and efficacy of intravenous diltiazem in the treatment of 37 patients with rapid (ventricular rate, mean ± SD 142 ± 17 beats/min) atrial fibrillation or flutter and moderate to severe congestive heart failure (ejection fraction, mean ± SD 36 ± 14%; New York Heart Association class III [23 patients], class IV [14 patients]). During the double-blind portion of the study, patients received either intravenous diltiazem, 0.25 mg/kg over 2 minutes, or placebo followed 15 minutes later by diltiazem or placebo, 0.35 mg/kg over 2 minutes, if the first dose was tolerated but ineffective. Placebo nonresponders were given open-label intravenous diltiazem in a similar fashion as in the double-blind portion of the study. In the double-blind part of the study, 21 (18 with 0.25 mg/kg, 3 with an additional 0.35 mg/kg) of the 22 patients (95%) responded to diltiazem, and 0 of 15 patients (0%) responded to placebo (p < 0.001). All 15 patients (13 with 0.25 mg/kg and 2 with an additional 0.35 mg/kg) who received placebo during the double-blind period had a therapeutic response to diltiazem during open-label therapy. Overall, 36 of 37 patients (97%) had a therapeutic response to intravenous diltiazem. Heart rate response to diltiazem after the 2-minute bolus infusions consisted of a ≥20% decrease in heart rate from baseline in 36 patients; in addition, 17 patients also had heart rates decreased to <100 beats/min, whereas no patient had conversion to sinus rhythm. The median time to response from the beginning of the 2-minute bolus dose of diltiazem was about 5 minutes. Hypotension was the most common adverse event occurring in 4 of the 37 patients (11%). No patient had an exacerbation of congestive heart failure due to diltiazem. In conclusion, intravenous diltiazem is rapid, safe, and effective in acutely lowering a rapid ventricular rate in patients with atrial fibrillation or flutter and moderate to severe congestive heart failure.

Original languageEnglish (US)
Pages (from-to)884-889
Number of pages6
JournalThe American journal of cardiology
Volume74
Issue number9
DOIs
StatePublished - Nov 1 1994

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure'. Together they form a unique fingerprint.

  • Cite this